TL;DR
The White House withdrew Heidi Overton’s nomination to lead the FDA on Tuesday, Nov. 17, 2026, ahead of a Senate committee vote scheduled for Wednesday. The move followed signs that she lacked the Republican support needed to advance, including continued uncertainty from committee chair Bill Cassidy over her independence on vaccine policy.
The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration on Tuesday, Nov. 17, 2026, after signs she did not have enough Senate support to advance. The decision came a day before a scheduled committee vote and leaves the FDA under acting leadership while President Donald Trump’s administration considers its next steps.
Get everyday essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Overton, a physician with a doctorate and a White House domestic policy adviser, was nominated in August. She had spent much of her career working for Trump or conservative groups aligned with his agenda. Her nomination was presented as a potential stabilizing appointment after a difficult period at the FDA under former commissioner Marty Makary.
The immediate obstacle was support on the Senate Health, Education, Labor, and Pensions Committee. Republicans hold 12 of the committee’s 23 seats, while Democrats hold 11, meaning Overton needed every Republican member to vote for her to advance. Committee chair Sen. Bill Cassidy, a Louisiana Republican, said Tuesday he remained undecided before the scheduled vote.
Cassidy had questioned whether Overton would act independently of Trump and Health Secretary Robert F. Kennedy Jr., particularly over vaccine policy. At a September hearing, he pressed her on whether she would challenge the administration’s positions. He had also described her support for Trump’s proposal to break up combination vaccines, including the measles, mumps and rubella vaccine, as “almost disqualifying.”
Why the White House Pulled Its FDA Nominee A leadership gap remains
Heidi Overton’s nomination was withdrawn a day before a Senate committee vote. Uncertain Republican support and questions about vaccine policy independence left the FDA’s permanent leadership unresolved.
Why the nomination stalled
The committee split made every Republican vote consequential.
- Republicans held 12 of 23 committee seats.
- Chair Bill Cassidy remained undecided.
- Cassidy questioned Overton’s independence from Trump and Robert F. Kennedy Jr.
- Vaccine policy was a central point of scrutiny.
What the withdrawal means
The agency’s permanent leadership remains unresolved.
Acting commissioner
Kyle Diamantas is leading the FDA on an acting basis; no permanent replacement date has been announced.
Operational uncertainty
The FDA oversees food, medicines, vaccines and medical devices. Leadership decisions shape public health policy and daily regulation.
What happens next
The withdrawal leaves both the committee’s next move and the White House’s next nominee unclear.
A vote was scheduled for Nov. 18, but its status after the withdrawal has not been specified.
The administration has not announced another nominee or a timetable for a permanent commissioner.
Democrats are due to take control of the chamber in January, adding pressure to resolve nominations beforehand.
A Leadership Gap at the FDA
The withdrawal leaves the FDA without a Senate-confirmed commissioner and extends uncertainty over who will direct the agency’s work. The FDA oversees food safety, medicines, vaccines and medical devices, so leadership decisions can affect both public health policy and the agency’s day-to-day regulatory operations.
The need for stable leadership is sharpened by reported turnover and internal strain. The FDA has lost about 20% of its employees since Trump took office through layoffs, buyouts, retirements and resignations. That figure describes the period since his return to office; it does not establish how much of the loss resulted from any single policy or leadership decision.
The failed nomination also shows the limits of the administration’s ability to move health appointments through the Senate when Republican support is uncertain. With Democrats due to take control of the chamber in January, Republicans have been trying to confirm Trump’s nominees before the change in control. The withdrawal removes one nominee from that effort and leaves the FDA’s permanent leadership unresolved.
Popular right now

Ninja Foodi 8-Quart DualZone 6-in-1 Air Fryer, Grey (DZ201)

Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation

Dyson V8 Cyclone Cordless Vacuum
As an affiliate, we earn on qualifying purchases.
Questions Over Vaccine Independence
Overton’s nomination followed a tumultuous year at the FDA under Makary, which was marked by scientific disputes, leadership changes and reports of low morale and internal dysfunction. The White House’s August choice of a Trump-aligned adviser was viewed as an attempt to bring steadier political leadership to the agency, but her ties to the administration became a focus of Senate scrutiny.
That scrutiny centered on whether she would maintain scientific independence, especially on vaccines. Cassidy had previously threatened to withhold support from health nominees unless they committed to maintaining vaccine standards, including Kennedy. He ultimately voted for each nominee who came before his committee, but his continued indecision over Overton left her prospects uncertain.
Opposition also came from some influential figures in the Make America Healthy Again movement, who argued that Overton and other White House officials had sidelined parts of Kennedy’s agenda. Earlier in November, Calley Means told Joe Rogan that White House aides, including Overton, had worked to advance a Supreme Court decision blocking thousands of lawsuits over the weedkiller glyphosate. Means alleged that the decision and other policies reflected industry lobbyist influence; that allegation is not independently established by the information available here.
“He remained undecided about Overton.”
— Sen. Bill Cassidy, speaking before the scheduled committee vote
The Next FDA Nominee Is Unknown
The White House’s announcement establishes that Overton’s nomination was withdrawn, but the available information does not specify who requested the withdrawal or whether the administration plans to nominate another candidate immediately. It is also unclear how the committee vote scheduled for Wednesday will be handled now that Overton is no longer the nominee.
The precise Senate vote count was not reported. Cassidy’s indecision and the requirement for unanimous Republican committee support indicated a serious risk, but they do not establish how every senator would have voted. The administration has not provided a new timetable for confirming a permanent FDA commissioner.
Other details remain contested. Means’s claims about White House involvement in the glyphosate litigation decision and influence by industry lobbyists are his allegations, not confirmed findings. The circumstances of Overton’s withdrawal and any commitments she may have offered privately also remain unclear.
Senate and White House Next Steps
The Senate committee’s scheduled Wednesday vote was the next immediate milestone, though Overton’s withdrawal may change or remove that item from the agenda. The White House will need to decide whether to put forward another nominee and when, while senators may continue considering other pending Trump nominees before Democrats assume control of the chamber in January.
For now, the FDA is being led on an acting basis by Kyle Diamantas, an attorney and friend of Donald Trump Jr. Diamantas previously served as the agency’s top food official and was elevated to the acting post by Trump. No date for a permanent replacement has been announced.
Readers can expect further clarity from the White House or the committee on the status of the scheduled vote and any new nomination. Until then, the agency remains under acting leadership, and the administration’s approach to securing a confirmed commissioner is unresolved.
Source: rss
Key Questions
Why was Heidi Overton’s FDA nomination withdrawn?
The White House withdrew the nomination amid indications Overton lacked enough support to advance in the Senate committee. The exact vote count and who initiated the withdrawal have not been reported.
What role did Bill Cassidy play?
Cassidy chaired the Senate health committee and said he remained undecided before the scheduled vote. Overton needed all 12 Republican committee members to support her to advance, making his position consequential.
Who is leading the FDA now?
The FDA is being led on an acting basis by Kyle Diamantas, who previously served as the agency’s top food official. The White House has not announced a date for a permanent replacement.
What happens to the scheduled committee vote?
A vote had been scheduled for Wednesday, Nov. 18, 2026, but Overton’s withdrawal may change or remove it from the agenda. The committee’s next action has not been specified.
Source: medpagetoday.com
